Rhumbline Advisers Grows Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Rhumbline Advisers increased its holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,202 shares of the company’s stock after purchasing an additional 1,027 shares during the period. Rhumbline Advisers owned 0.05% of Tyra Biosciences worth $364,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TYRA. Charles Schwab Investment Management Inc. grew its stake in Tyra Biosciences by 2.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock valued at $4,085,000 after acquiring an additional 3,792 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Tyra Biosciences by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after purchasing an additional 3,896 shares in the last quarter. Ally Bridge Group NY LLC boosted its holdings in shares of Tyra Biosciences by 2.0% during the 3rd quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock valued at $6,349,000 after purchasing an additional 5,415 shares during the last quarter. Oppenheimer & Co. Inc. grew its position in shares of Tyra Biosciences by 9.0% during the third quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock valued at $1,806,000 after purchasing an additional 6,318 shares in the last quarter. Finally, Jennison Associates LLC increased its holdings in shares of Tyra Biosciences by 5.9% in the third quarter. Jennison Associates LLC now owns 158,187 shares of the company’s stock worth $3,719,000 after purchasing an additional 8,837 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TYRA. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group began coverage on Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $30.50.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the transaction, the director now directly owns 3,707,420 shares in the company, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 21,998 shares of company stock worth $344,818. Company insiders own 15.40% of the company’s stock.

Tyra Biosciences Price Performance

NASDAQ:TYRA opened at $10.94 on Monday. The firm has a market capitalization of $553.60 million, a price-to-earnings ratio of -6.79 and a beta of 1.09. The business has a 50 day simple moving average of $13.90 and a 200-day simple moving average of $17.46. Tyra Biosciences, Inc. has a 1 year low of $10.65 and a 1 year high of $29.60.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.